Curis Inc (CRIS US): Synthetic Expert Call Transcript (13 Aug 2026)
Primary CNS Lymphoma (PCNSL) Niche as a Double-Edged Sword: While emavusertib has demonstrated a 100% ORR in 5 evaluable BTK-naïve PCNSL patients...
89 Views
IPO Databook: Curis (CRIS US) - Aug 2026
Curis, Inc. is a biotechnology company developing emavusertib, an orally available small molecule inhibitor of IRAK4 and FLT3, evaluated in...
95 Views
Primer: Curis Inc (CRIS US) - Aug 2026
Curis is a clinical-stage biotechnology company centered on the development of its lead candidate, emavusertib, an oral small molecule inhibitor...
97 Views
No more insights